PD-1 inhibitors, such as pembrolizumab and nivolumab, exert therapeutic effects primarily by blocking the interaction between the PD-1 receptor on T cells and its ligand, PD-L1, expressed on tumor cells. This evidence concerns the gene PDCD1 and neoplasm.